-
Lumiracoxib: Selective COX-2 Research Guide
2026-09-10
Lumiracoxib is a selective COX-2 inhibitor for research on prostaglandin synthesis inhibition, inflammation, and tissue-repair signaling. Supplier specifications and a peer-reviewed muscle-injury study indicate that its biological effects depend on assay selectivity, exposure timing, and the measured vascular endpoint.
-
Developmental SSRI Exposure and Motivational Deficits
2026-09-10
A 2026 Columbia University dissertation shows that developmental SSRI exposure produces persistent, motivation-specific reward deficits in adolescent and adult mice. Progressive-ratio behavior improved after mu opioid receptor antagonism or nucleus accumbens MOR knockdown, identifying a circuit-level intervention distinct from subsequent SSRI treatment.
-
Tunicamycin in CVA: ER Stress and NLRP3
2026-09-09
The 2019 reference study identified endoplasmic reticulum stress as a mechanistic link between pulmonary dysfunction and NLRP3 inflammasome activation in cough variant asthma. Tunicamycin was used as a pharmacological stress challenge to test whether Suhuang antitussive capsule protected the lung by suppressing this pathway.
-
Epoxomicin Workflows for Proteasome Research
2026-09-09
Epoxomicin is a selective, irreversible proteasome inhibitor for connecting proteasome activity with protein turnover, inflammatory signaling, and viral pathogenesis. This workflow-focused guide shows how to prepare, dose, validate, and troubleshoot Epoxomicin in enzyme, cell-based, and RIPK3 degradation assays.
-
Lypressin Acetate: From Receptor Biology to Translation
2026-09-08
Lypressin acetate, also known as lysine vasopressin acetate, links vasopressin receptor pharmacology with translational research in diabetes insipidus, vasoconstriction, hemostasis, and exploratory SARS-CoV-2 RdRp studies. This article outlines how researchers can convert its receptor activity and peptide-handling requirements into disciplined experimental and strategic decisions.
-
IPR-803: Reliable uPAR Inhibition Workflows
2026-09-08
This scenario-driven guide explains how IPR-803, SKU BA8331, can support interpretable uPAR–uPA studies across viability, invasion, angiogenesis, and metastasis workflows. It separates biochemical potency from cellular dosing, highlights model-dependent readouts, and provides practical selection and handling guidance for laboratory teams.
-
Cell Counting Kit-8 Workflows in Ovarian Cancer
2026-09-07
Cell Counting Kit-8 (CCK-8) converts viable-cell metabolic activity into a practical, plate-based readout for proliferation, toxicity, and exosome-driven cancer phenotypes. This guide translates ovarian cancer macrophage-polarization research into controlled assay workflows, optimization steps, and troubleshooting decisions.
-
Clozapine Workflows for Schizophrenia Research
2026-09-05
Clozapine enables receptor-informed, pathway-focused studies spanning prefrontal neuronal signaling, antipsychotic pharmacology, and hepatotoxicity studies. This workflow connects its ERK1/2 and EGF receptor biology with the reference study’s targeted magnetic-stimulation model while clearly separating established evidence from testable extensions.
-
Liproxstatin-1 Ferroptosis Workflows
2026-09-05
Build more discriminating ferroptosis assays with Liproxstatin-1, from GPX4-deficient cell protection to renal injury studies. This workflow-focused guide pairs pathway controls, lipid-peroxidation readouts, formulation guidance, and a careful comparison with cuproptosis research.
-
Lyso-Tracker Red for Nanovaccine Trafficking
2026-09-04
Lyso-Tracker Red can add a live-cell acidic-compartment readout to nanoparticle vaccine studies. This article explains how to interpret lysosomal localization, uptake, and escape without treating fluorescence as proof of immune efficacy.
-
Gamithromycin PK/PD in Rabbit Pasteurellosis
2026-09-04
The 2024 BMC Veterinary Research study defined rabbit-specific pharmacokinetic and pharmacodynamic targets for Gamithromycin against Pasteurella multocida. Its integration of rabbit plasma exposure, time-kill behavior, post-antibiotic effects, and AUC/MIC modeling provides a quantitative framework for evaluating rabbit pasteurellosis therapy while highlighting the limits of extrapolating data from cattle or pigs.
-
Concanamycin A: V-ATPase Inhibitor Guide
2026-09-03
Concanamycin A is a potent V-type H+-ATPase inhibitor used to interrogate organelle acidification, intracellular trafficking, apoptosis, and invasion in cancer models. Product information reports an approximately 10 nM IC50, while the literature supports V-ATPase-dependent effects as a mechanistic research framework rather than evidence of clinical efficacy.
-
Ceftolozane Sulfate: Assay-to-PK/PD Strategy
2026-09-03
Ceftolozane sulfate research is strongest when MIC testing, resistance interpretation, and exposure–response modeling are designed as one workflow. This guide connects PBP3 biology with susceptibility assays, resistant Pseudomonas phenotypes, and translational PK/PD decisions.
-
NSP15 Screening Identifies Thymopentin and Oleuropein
2026-09-02
A 2021 structure-based study screened a natural-product library against the SARS-CoV-2 NSP15 endoribonuclease and identified thymopentin and oleuropein as the strongest predicted binders. Docking followed by molecular-dynamics simulations supported complex stability, but the computational findings require biochemical and cellular validation before either compound can be considered an antiviral inhibitor.
-
Asunaprevir: Translational Lessons Beyond HCV
2026-09-02
Asunaprevir (BMS-650032) illustrates how direct antiviral potency becomes translationally meaningful when target engagement, genotype coverage, cellular replication, and hepatic exposure are evaluated as one evidence chain.